Loading...
XSHE
002653
Market cap9.94bUSD
Oct 09, Last price  
61.02CNY
1D
2.71%
1Q
-11.99%
Jan 2017
332.42%
IPO
1,051.89%
Name

Haisco Pharmaceutical Group Co Ltd

Chart & performance

D1W1MN
XSHE:002653 chart
P/E
263.26
P/S
15.72
EPS
0.23
Div yield, %
0.45%
Shrs. gr., 5y
0.92%
Rev. gr., 5y
5.47%
Revenues
4.35b
+16.80%
358,762,468484,571,191581,585,122604,429,653802,069,347992,337,3011,210,595,3831,212,453,3431,435,606,5861,856,160,9253,426,664,2583,937,340,4613,329,599,5742,773,314,8843,015,294,3393,355,070,1083,721,349,2344,346,357,012
Net income
260m
-34.36%
195,086,739283,719,337305,752,954312,296,110443,060,917519,218,916450,541,064372,157,952442,778,892237,553,216333,228,521493,891,817636,621,373345,058,654277,072,550295,111,616395,455,242259,579,779
CFO
797m
+80.32%
94,445,426368,213,627367,380,976260,794,014464,751,585568,414,763502,568,128443,027,933409,195,107391,810,909472,607,295764,259,511206,207,63635,801,45994,546,036449,578,350442,045,668797,078,494
Dividend
Sep 04, 20260.526 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.

Key people

Peng Duan
Chief Financial Officer · since 2016
Ruibin Wang
Deputy General Manager · since 2025
Meng Wang
Deputy General Manager, Secretary of the Board · since 2015
Xiulian Fan
Director · since 2025
Junmin Wang
Chairman of the Board · since 2019
Pangke Yan
General Manager, Director · since 2025
Chuande Cao
Independent Director · since 2023
Jun Le
Independent Director · since 2020
Lin Yue
Independent Director · since 2023
IPO date
Jan 17, 2012
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
萨市西藏山南市泽当镇三湘大道17号
拉萨市, XZ 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT